LOM Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

LOM Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$777K	Hold	1,565	–	–	0.2%	105
2026 Q1	$699K	Hold	1,565	–	–	0.2%	114
2025 Q4	$710K	Hold	1,565	–	–	0.21%	112
2025 Q3	$613K	Hold	1,565	–	–	0.19%	120
2025 Q2	$697K	Buy	+1,565	New	+$721K	0.24%	113

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

LOM Asset Management's VRTX Position: Q2 2026 in Review

LOM Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1,565 shares worth $777K. The position accounts for 0.2% of the portfolio, ranked #105.

LOM Asset Management first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

LOM Asset Management held 1,565 shares of Vertex Pharmaceuticals worth $777K as of Q2 2026.
LOM Asset Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.2% of LOM Asset Management's portfolio in Q2 2026, its #105 holding.
LOM Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LOM Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.